ThermoGenesis Launches Comprehensive Suite of COVID-19 Products and Services to Better Detect, Track and Fight Novel Coronavirus

ThermoGenesis Holdings, Inc. (Rancho Cordova, CA, USA), along with its joint venture ImmuneCyte Life Sciences, Inc.’s (Irvine, CA, USA), has launched a comprehensive COVID-19 product line that will combine diagnostic, therapeutic and service offerings to better detect, track and fight the novel coronavirus.

The spread of COVID-19 has led to a significant unmet need for rapid disease diagnosis, systematic serological surveillance and improved therapeutics, to precede and complement the introduction of vaccines. In response, ThermoGenesis, along with its joint venture ImmuneCyte, is developing a comprehensive list of RT-PCR and antigen test products to complement its SARS-CoV-2 IgM/IgG Antibody Test Kit, which has already been granted Emergency Use Authorization (EUA). The joint venture also plans to offer full CLIA certified lab testing services to its clients, making ThermoGenesis a one-stop shop for all testing needs. Additionally, the ImmuneCyte joint venture is actively developing a robust therapeutic pipeline to treat COVID-19.


"The comprehensive diagnostic and therapeutic product pipeline we envisage for COVID-19 will facilitate ThermoGenesis' ability to become a one-stop solution for our customers," said Chris Xu, Ph.D, Chairman and Chief Executive Officer of ThermoGenesis. "This multi-pronged approach, we believe, will be critical to reopening the economy, tracking the virus, and minimizing the loss of life as we continue to develop and expand our product solutions for COVID-19."

Related Links:
ThermoGenesis Holdings, Inc.
ImmuneCyte Life Sciences, Inc.